Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keywan Mortezaee

Showing results (41-50 of 142) with videos related to

Pageof 15
Sort By:
International Journal of Clinical Oncology|November 13, 2021
Key promoters of tumor hallmarksKeywan Mortezaee, Jamal Majidpoor
Heliyon|March 23, 2023
Anti-PD-(L)1 therapy of non-small cell lung cancer-A summary of clinical trials and current progressesKeywan Mortezaee, Jamal Majidpoor
Current Medicinal Chemistry|January 22, 2024
An Update of Extracellular Vesicle Involvement in Different Steps of Cancer Metastasis and Targeting StrategiesKeywan Mortezaee, Jamal Majidpoor
Heliyon|December 25, 2023
Alternative immune checkpoints in immunoregulatory profile of cancer stem cellsKeywan Mortezaee, Jamal Majidpoor
Cellular Oncology (Dordrecht, Netherlands)|May 19, 2022
Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapyKeywan Mortezaee, Jamal Majidpoor
International Immunopharmacology|July 4, 2021
Interleukin-2 therapy of cancer-clinical perspectivesJamal Majidpoor, Keywan Mortezaee
Medical Oncology (Northwood, London, England)|September 29, 2022
Extracellular vesicle-based checkpoint regulation and immune state in cancerKeywan Mortezaee, Jamal Majidpoor
Frontiers in Oncology|February 11, 2022
(Im)maturity in Tumor EcosystemKeywan Mortezaee, Jamal Majidpoor
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 2, 2023
Reinstating immunogenicity using bispecific anti-checkpoint/agent inhibitorsKeywan Mortezaee, Jamal Majidpoor
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 4, 2023
Mechanisms of CD8<sup>+</sup> T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1Keywan Mortezaee, Jamal Majidpoor
Pageof 15

Showing results (41-50 of 142) with videos related to

Sort By:
Pageof 15
International Journal of Clinical Oncology|November 13, 2021
Key promoters of tumor hallmarksKeywan Mortezaee, Jamal Majidpoor
Heliyon|March 23, 2023
Anti-PD-(L)1 therapy of non-small cell lung cancer-A summary of clinical trials and current progressesKeywan Mortezaee, Jamal Majidpoor
Current Medicinal Chemistry|January 22, 2024
An Update of Extracellular Vesicle Involvement in Different Steps of Cancer Metastasis and Targeting StrategiesKeywan Mortezaee, Jamal Majidpoor
Heliyon|December 25, 2023
Alternative immune checkpoints in immunoregulatory profile of cancer stem cellsKeywan Mortezaee, Jamal Majidpoor
Cellular Oncology (Dordrecht, Netherlands)|May 19, 2022
Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapyKeywan Mortezaee, Jamal Majidpoor
International Immunopharmacology|July 4, 2021
Interleukin-2 therapy of cancer-clinical perspectivesJamal Majidpoor, Keywan Mortezaee
Medical Oncology (Northwood, London, England)|September 29, 2022
Extracellular vesicle-based checkpoint regulation and immune state in cancerKeywan Mortezaee, Jamal Majidpoor
Frontiers in Oncology|February 11, 2022
(Im)maturity in Tumor EcosystemKeywan Mortezaee, Jamal Majidpoor
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 2, 2023
Reinstating immunogenicity using bispecific anti-checkpoint/agent inhibitorsKeywan Mortezaee, Jamal Majidpoor
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 4, 2023
Mechanisms of CD8<sup>+</sup> T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1Keywan Mortezaee, Jamal Majidpoor
Pageof 15